コンテンツへスキップ
Merck

Ribosomal s6 protein kinase 4: a prognostic factor for renal cell carcinoma.

British journal of cancer (2013-08-15)
L Fan, P Li, Z Yin, G Fu, D J Liao, Y Liu, J Zhu, Y Zhang, L Wang, Q Yan, Y Guo, C Shao, G Huang, Z Wang
要旨

The expression and function of ribosomal s6 protein kinase 4 (RSK4) in renal cell carcinoma (RCC) are unknown. Immunohistochemistry was used to detect the expression of RSK4 in RCC, and the relationship between RSK4 expression and clinicopathological features as well as prognosis of RCC patients was statistically analysed. Ectopic RSK4 expression in RCC cell lines was performed to determine its effect on cell cycle regulation, tumour invasiveness, and metastatic capability. RSK4 was overexpressed in RCCs (P=0.003), compared with normal tissues, and the expression varied in different RCC subtypes (P=0.021), especially in two subtypes of papillary RCCs (P=0.001). RSK4 expression was positively correlated with high pT stage (P<0.001), high Fuhrman grade (P<0.001), lymph node involvement (P<0.001), and presence of distant metastasis (P=0.039), and could predict poor outcome in RCC patients. Molecular studies showed that overexpression of RSK4 could promote cell cycle progression and enhance the invasive and metastatic capability of RCC cell lines and vice versa. The expression pattern and molecular mechanisms of RSK4 in RCCs indicate that it could be a potential independent prognostic factor and serve as a new potential therapeutic target for RCC patients.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
MISSION® esiRNA, targeting human RPS6KA6